drugset / Trial / NCT00161434
A Study of Valacyclovir to Suppress HSV and HIV Shedding in Coinfected Persons
Phase 4
Completed
60 enrolled
University of Washington
GlaxoSmithKline · collabNational Institutes of Health (NIH) · collab
RandomizedCrossoverDouble-blindPrevention
Summary
The primary objective of this research study is to assess if daily valacyclovir therapy for suppression of HSV-2 reactivation is associated with a decrease in mucosal HIV shedding in individuals co-infected with both HSV-2 and HIV.
Timeline
- Start
- 2003-03
- Primary completion
- 2006-06
- Completion
- 2006-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Valacyclovir | Unknown | 1 g | — |